Dermatology Medical News about Infections

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Antimicrobial Agents for Complicated Skin and Skin-Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo-Controlled Trials
Clinical Infectious Diseases, 07/08/09

Spellberg B et al. - Systematic review of historical literature enables rational noninferiority margin justification in the absence of placebo-controlled trials and may facilitate regulatory review of noninferiority trials. Noninferiority margins of 14% for cellulitis/erysipelas, 21% for wound/ulcer infections, and 7% for major abscesses would preserve>50% of antibiotic efficacy versus placebo for these complicated SSSI subsets.

Exclusive Author Commentary
Dr. Brad Spellberg, 07/08/09

Regulatory confusion regarding appropriate clinical trial designs is creating a major barrier to the development of badly needed new antibiotics. A primary cause of regulatory confusion relates to the complexities of non-inferiority trial design. Because placebo is not tested in a non-inferiority trial, there are two possible conclusions to be drawn when an experimental drug is found to be "non-inferior" to the comparator drug in a clinical trial: 1) both the experimental and comparator drugs are superior in efficacy to placebo; and 2) neither the experimental or comparator drug are superior in efficacy to placebo. The only way to exclude the latter possibility is to be certain, based on a previously published placebo-controlled study, that the comparator drug used in the non-inferiority study is superior in efficacy to placebo. Unfortunately, antibiotics became available in an era prior to the use placebo-controlled studies, and most serious forms of infections have never been studied in placebo-controlled studies. This fact makes regulatory review of non-inferiority studies of infections very complicated. We sought to provide an alternative mechanism to establishing the magnitude of superiority of standard antibiotic therapy to placebo/no therapy. We conducted a systematic literature review of literature from the pre- and immediate post-antibiotic era and calculated weighted average cure rates for complicated skin and skin structure infections treated with anti-bacterials or non antibiotic treatments. By comparing cure rates with and without anti-bacterials, we were able to provide a conservative estimate of the magnitude of antibiotic efficacy for these infections, thereby enabling justification of non-inferiority margins to be used in modern non-inferiority studies of complicated skin and skin structure infections. It is hoped that these results will provide clarity to appropriate trial design for these infections.

<< Previous
Patients with Merkel cell carcinoma tumors ≤1.0 cm in diameter...

Next >>
Immunophenotypic Pattern and Cytokine Profiles of Dry Type...